Elsevier

Life Sciences

Volume 70, Issue 1, November 2001, Pages 97-108
Life Sciences

Original articles
Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats

https://doi.org/10.1016/S0024-3205(01)01366-2Get rights and content

Abstract

Lewis rats were trained to self-stimulate the medial forebrain bundle (MFB) using a rate-frequency paradigm. They were then tested for the effects of the cannabinoid receptor agonist CP 55,940, the selective cannabinoid receptor antagonist SR 141716 and the dopamine D1 receptor antagonist SCH 23390. CP 55,940 (0, 10, 25 and 50 μg/kg i.p.) had no effect on MFB self-stimulation behaviour as assessed by the M50, the stimulation frequency at which half-maximal response rates were obtained. With SR 141716, only a very high dose (20 mg/kg i.p.) caused a significant inhibition of the rewarding efficacy of the stimulation. This was seen as an increase in the M50. All other doses of SR 141716 (0, 1, 3, 10 mg/kg i.p.) were ineffective in modulating the M50. By comparison, a relatively low dose (0.06 mg/kg i.p.) of SCH 23390 caused a large increase in M50. These results indicate a relatively modest influence, if any at all, of exogenous or endogenous cannabinoids on reward-relevant neurotransmission.

References (0)

Cited by (48)

  • The Interactive Nature of Cannabis and Schizophrenia Risk Genes

    2017, Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment
  • Dissociating the role of endocannabinoids in the pleasurable and motivational properties of social play behaviour in rats

    2016, Pharmacological Research
    Citation Excerpt :

    Blocking CB1 cannabinoid receptors with rimonabant reduced operant responding for social play. In previous studies, treatment with rimonabant was found to reduce operant responding for food [16,32,49,77], chocolate-drinks [28] but not intracranial self-stimulation [4]. Rimonabant treatment also reduced the intake of food [72–74] chocolate-drink, and ethanol [5], suggesting that a decrease in the pleasurable properties of rewards contributes to the reduction in operant responding induced by rimonabant.

  • Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice

    2015, Drug and Alcohol Dependence
    Citation Excerpt :

    Intracranial self-stimulation (ICSS) of the medial forebrain bundle is one procedure that has been used to measure reinforced behavior mediated by the mesolimbic dopamine pathway (Carlezon and Chartoff, 2007) and to assess abuse potential of drugs (Negus and Miller, 2014). Although acute administration of synthetic cannabinoids generally suppresses ICSS (Arnold et al., 2001; Vlachou et al., 2003, 2005), the impact of repeated cannabinoid administration on ICSS has not been extensively studied but may be important. For example, repeated administration of mu opioid agonists evokes tolerance to their rate-decreasing effects and unmasks abuse-related ICSS facilitation (Altarifi and Negus, 2011; Altarifi et al., 2012).

  • Phytocannabinoids as novel therapeutic agents in CNS disorders

    2012, Pharmacology and Therapeutics
    Citation Excerpt :

    Together these effects imply that the stimulation of feeding induced by ∆9-THC may be linked to the appetitive phase of feeding, being associated with orienting an animal toward food and increasing the salience or reward value of food stimuli. The concept of cannabinoids influencing reward processes is well-established and has been supported by findings that blockade of CB1 receptors by SR141716A reduced sensitivity to the rewarding effects of electrical brain stimulation (Arnold et al., 2001; Deroche-Gamonet et al., 2001) and blocked the acquisition of drug- or food induced place preferences (Chaperon et al., 1998). Conversely, stimulation of CB1 receptors underlie the motivation to obtain and ingest palatable ingesta (Gallate & Mcgregor, 1999; Gallate et al., 1999; Higgs et al., 2003).

  • Cannabinoids increase conditioned ultrasonic vocalisations and cat odour avoidance in rats: Strain differences in drug-induced anxiety

    2010, Life Sciences
    Citation Excerpt :

    The synthetic cannabinoid receptor agonist CP 55,940 ((–)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol) (a generous gift from Pfizer Ltd, Sydney) was used in all studies. CP 55,940 promotes a similar constellation of neurobehavioural effects to ∆9-tetrahydrocannabinol (THC) (Arnold et al., 1998, 2001a,b) and fully substitutes for THC in the drug discrimination paradigm (Gold et al., 1992). The peak effect and duration of action of CP 55,940 is almost identical to that of THC.

View all citing articles on Scopus
View full text